• Stoke Therapeutics filed a prospectus supplement for an at-the-market offering of up to USD 200 million of common stock.
• Shares may be sold from time to time under its controlled equity sales agreement with Cantor Fitzgerald.
• The offering uses the company’s Form S-3 automatic shelf registration statement filed March 18, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-330804), on August 03, 2026, and is solely responsible for the information contained therein.